Businesswire, page-25

You are mistaking balanced comment with facts and implying it is downramping.  It is a shame you don't ask the question in a nice manner as you have with the uninformed, exaggerated upramping style comments as well?  Perhaps if you did, or did the research you would know that 20% of patients are under 1 yo and a further 10% are under 18 yo and aren't approved to receive recell and then take out hand burns that make up a % as well . Its not that Avita management don't know the numbers  (well I hope they do) but the numbers start to look very different when you look at the population they are allowed to treat and is economical to do so.  But hey that smaller number doesn't look good in a presentation to punters does it so you'll trust the management numbers 100% as it is not as if they ever want anything other than money from you and they have been 100% right with timing etc? How far back in your posts would I need to go to see doubts? .  Interesting to note there is no other comment on stratograft , the price that was just paid for it and the barda funding it has for trial completion,and barda stockpile.  Why would a listed NYSE company buy that when they could have bought Avita is a good question.